The Patent Trial and Appeals Board upheld parts of Arbutus Biopharma Corp.'s U.S. Patent Nos. 9,364,435 and 8,058,069, on drug-delivery technology. Arbutus argues Moderna has no standing to appeal those decisions because Moderna hasn’t suffered any injury related to the patents.
Moderna will tell the U.S. Court of Appeals for the Federal Circuit that there is a substantial risk that Arbutus will sue, accusing various Moderna products of infringing the patents. ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
